Hepatitis C treatment with glecaprevir-pibrentasvir during pregnancy in women who use drugs
Looks at glecaprevir-pibrentasvir for hepatitis C in pregnant women who use drugs.
Key facts
- Who runs it
- Washington University School of Medicine
- Where
- St Louis, United StatesSee the 2 sites
- Trial code
- Registry title
- Feasibility and Acceptability of HCV Treatment in Pregnancy
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 1 Feb 2024
- Expected to end
- 28 Dec 2026
- Type of study
- Observational
- Treatments tested
- Glecaprevir-pibrentasvir
- Record updated
- 9 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women aged 18 or older who have hepatitis C virus infection and have used drugs in the past or use them now. They will take glecaprevir-pibrentasvir during pregnancy.
- Age
- 18 years or older
- Sex
- Female
- Disease stage
- Hepatitis C virus infection, diagnosed. Must be pregnant when joining the trial.
This trial only enrols pregnant participants. The registry sentence this rests on: * Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use
Who cannot take part
- -
Where in United States
- Barnes-Jewish HospitalSt Louis, United StatesContact: Tracey BachTaking people
- Washington UniveristySt Louis, United StatesContact: Laura Marks, MD,PhDTaking people
About the trial
What the trial wants to find out
Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use
Read full original descriptionShow less
Participant Duration: Approximately 1 year.
Aims:
Aim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs.
Aim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.
The group in the trial
- Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c
Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.
Treatment: Glecaprevir-pibrentasvir
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy
- Plain-language title
- Hepatitis C treatment with glecaprevir-pibrentasvir during pregnancy in women who use drugsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 June 2026